Articles
| Open Access |
https://doi.org/10.55640/
DIAGNOSIS OF ANXIETY AND DEPRESSION IN MOTOR NEURON DISEASE WITH CLINICAL-NEUROLOGICAL METHODS
Ravzatov Jasurbek Bakhromovich,Akbarova Saida Bakhtiyorovna , PhD, assistant of the department of training family doctors of Andijan state medical institute, Uzbekistan,PhD, assistant of Normal physiology department of Andijan state medical institute, Uzbekistan.Abstract
Motor neuron disease according to ICD-10 belongs to the class of diseases with systemic atrophy of the elements of the central nervous system. Motor neuron disease (MND) is also called amyotrophic lateral sclerosis (ALS). This disease is characterized by damage to the upper neurons of the brain with subsequent disruption of their connection with the spinal cord. As a result of the disease, paralysis of the whole body develops.
Keywords
Motor neuron disease, amyotrophic lateral sclerosis, degenerative processes, anxiety, depression.
References
Abati E., Bresolin N., Comi G., Corti S. Silence superoxide dismutase 1 (SOD1): a promising therapeutic target for amyotrophic lateral sclerosis (ALS). // Expert Opin Ther Targets. – 2020; 24 (4): 295–310.
Agah E., Saleh F., Sanjari Moghaddam H., et al. CSF and blood biomarkers in amyotrophic lateral sclerosis: protocol for a systematic review and meta-analysis // Syst. Rev. – 2018; 7: 237.
Akaishi T., Tateyama M., Kato K., et al. An autopsy case involving a 12-year history of amyotrophic lateral sclerosis with CIDP-like polyneuropathy // Intern Med. – 2014; 53(12): 1371–1375.
Al-Chalabi, A. Amyotrophic lateral sclerosis: moving towards a new classification system / A. Al-Chalabi, O. Hardiman, M.C. Kiernan // Lancet Neurol. – 2016. – Vol. 15. – № 11. – rr. 1182–1194.
Andrew A.S., Pioro E.P., Li M., et al. The incidence of amyotrophic lateral sclerosis in Ohio 2016–2018: the Ohio population-based ALS registry // Neuroepidemiology. – 2021; 55(3): 196–205.
Antao V.C., Horton D.K. The National Amyotrophic Lateral Sclerosis (ALS) Registry // Journal Environ Health. – 2012; 75: 28–30.
Antonescu F., Adam M., Popa C., Tuţă S. A review of cervical spine MRI in ALS patients // Journal Med. Life. – 2018; 11 (2): 123–127.
Axel F., Thomas W., Benjamin R., Wolfgang R. Haplo insufficiency of TBK1 causes familial ALS and fronto-temporal dementia // Nature Neuroscience. – 2015.
Bä umer D., Talbot K., Turner M.R. Advances in motor neurone disease // J R Soc Med. – 2014 Jan; 107(1): 14-21. DOI:10.1177/0141076813511451.
Bandres-Ciga S., Noyce A.J., Hemani G., et al. Shared polygenic risk and causal inferences in amyotrophic lateral sclerosis // Ann Neurol. – 2019. 85(4): 470–481.
Bedlack R.S., Vaughan T., Wicks P., Heywood J., et al. How common are ALS plateaus and reversals? // Neurology. – 2016; 86: 808–812.
Bello-Haas V.D. Physical therapy for individuals with amyotrophic lateral sclerosis: current insights // Degener Neurol Neuromuscul Dis. – 2018; 8: 45–54.
Benbrika S., Desgranges B., Eustache F., Viader F. Cognitive, Emotional and Psychological Manifestations in Amyotrophic Lateral Sclerosis at Baseline and Overtime: A Review // Front Neurosci. – 2019; 13: 951.
Bhandari R., Kuhad A., Kuhad A. Edaravone: a new hope for deadly amyotrophic lateral sclerosis // Drugs Today (Barc). – 2018; 54: 349–60.
Bledsoe M.J., Rechtman L., Wagner L., Mehta, et al. Analysis of biospecimen demand and utilization of samples from the National Amyotrophic Lateral Sclerosis Biorepository // Biopreserv Biobanking. – 2021; 19(5): 432–437.
Article Statistics
Downloads
Copyright License
This work is licensed under a Creative Commons Attribution 4.0 International License.